IDO1 and melanoma: The compound entered Phase I clinical testing (NCT03641794) to assess pharmacokinetics/pharmacodynamics in healthy volunteers and patients with advanced solid tumors, including glioblastoma, non-small cell lung carcinoma, and melanoma (Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers).